Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.
Jacob E. Berchuck, MD
Advertisement
Jacob E. Berchuck, MD, is ann assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute of Emory University.
Articles by Jacob E. Berchuck, MD
Jacob E. Berchuck, MD, discusses research on plasma epigenomic profiling in metastatic castration-resistant prostate cancer.
Jacob E. Berchuck, MD, discusses how a new epigenomic platform may influence the accessibility of PSMA-based therapies, especially for patients who may not have easy access to PSMA PET scans.
Jacob E. Berchuck, MD, discusses the potential of liquid biopsies to enhance clinical decision-making regarding PSMA-directed therapies.
Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented at the 2024 ESMO Congress.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
